Liminatus Pharma, Inc. (LIMN)
NASDAQ: LIMN · Real-Time Price · USD
4.155
-0.040 (-0.95%)
Sep 28, 2026, 11:48 AM EDT - Market open
Liminatus Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 3.02 | 0.34 | 0.06 | 0.43 | 5.05 | - |
Cash & Short-Term Investments | 3.02 | 0.34 | 0.06 | 0.43 | 5.05 | - |
Cash Growth | 125.46% | 499.54% | -87.02% | -91.40% | - | - |
Other Receivables | - | - | - | 0.13 | 0.1 | 0.05 |
Receivables | - | - | 3.67 | 0.95 | 0.1 | 0.05 |
Prepaid Expenses | 0.38 | 0.16 | 0.16 | 0.02 | 0.01 | - |
Other Current Assets | - | - | 1.4 | 0.84 | 1.68 | 2.64 |
Total Current Assets | 3.39 | 0.5 | 5.28 | 2.24 | 6.84 | 2.69 |
Property, Plant & Equipment | 0.01 | 0.01 | 0 | 0 | 0 | 0 |
Other Long-Term Assets | - | - | 0.13 | - | - | - |
Total Assets | 3.4 | 0.51 | 5.41 | 2.24 | 6.84 | 2.69 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.66 | 0.58 | 1.48 | 0.93 | 0.51 | 0.42 |
Accrued Expenses | 0.24 | 0.2 | 3.1 | 0.86 | 0.44 | 0.33 |
Short-Term Debt | 1.44 | 1.44 | 19.97 | 16.05 | 16.5 | 13.18 |
Other Current Liabilities | 0.7 | 8.07 | 0.2 | 0.2 | 0.2 | 0.14 |
Total Current Liabilities | 3.04 | 10.3 | 24.75 | 18.04 | 17.65 | 14.07 |
Other Long-Term Liabilities | 0.06 | 0.03 | - | - | - | - |
Total Liabilities | 3.1 | 10.33 | 24.75 | 18.04 | 17.65 | 14.07 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0 | 0 | 4.71 | 4.17 | 0.27 |
Additional Paid-In Capital | 41.7 | 29.05 | 9.32 | 4.61 | 5.16 | 5.56 |
Retained Earnings | -41.4 | -38.87 | -28.67 | -25.12 | -20.14 | -17.21 |
Shareholders' Equity | 0.3 | -9.81 | -19.34 | -15.79 | -10.81 | -11.38 |
Total Liabilities & Equity | 3.4 | 0.51 | 5.41 | 2.24 | 6.84 | 2.69 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.44 | 1.44 | 19.97 | 16.05 | 16.5 | 13.18 |
Net Cash (Debt) | 1.57 | -1.1 | -19.92 | -15.62 | -11.45 | -13.18 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | 2.27 | -2.33 | -56.90 | -7.62 | -16.10 | - |
Filing Date Shares Outstanding | 1.34 | 0.9 | 112.22 | 112.22 | 73.67 | - |
Total Common Shares Outstanding | 1.12 | 0.54 | 112.22 | 112.22 | 73.67 | - |
Working Capital | 0.35 | -9.8 | -19.47 | -15.8 | -10.81 | -11.38 |
Book Value Per Share | 0.27 | -18.13 | -0.17 | -0.14 | -0.15 | - |
Tangible Book Value | 0.3 | -9.81 | -19.34 | -15.79 | -10.81 | -11.38 |
Tangible Book Value Per Share | 0.27 | -18.13 | -0.17 | -0.14 | -0.15 | - |